申请人:Richter Gedeon Vegyeszeti Gyar
公开号:US04874765A1
公开(公告)日:1989-10-17
The invention relates to novel 1,4-disubstituted piperazine derivatives of the general formula (I), pharmaceutically acceptable acid addition and quaternary ammonium salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) ##STR1## R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are the same or different and stand for hydrogen or halogen or a trihalomethyl, lower alkyl, lower alkoxy, nitro, hydroxyl, aralkyloxy or an 1-(2-propenyl-4-piperazinyl) group; R.sub.5 stands for hydrogen or a C.sub.1-4 alkyl group; R.sub.6 represents a C.sub.3-6 alkyl, alkenyl, alkynyl group or a ##STR2## group, wherein R.sub.7 means a C.sub.2-5 alkyl, alkenyl or alkinyl group; and is 2 or 3, with the provisos that: R.sub.6 is different from isopropyl, n-butyl and isobutyl group when R.sub.2, R.sub.3, R.sub.4 and R.sub.5 stand for hydrogen, R.sub.1 means 2-chloro and n is 2; R.sub.6 is different from isopropyl group when R.sub.2, R.sub.3, R.sub.4 and R.sub.5 stand for hydrogen, R.sub.1 means 2-chloro and n is 2; or when R.sub.2, R.sub.3, R.sub.4 and R.sub.5 stand for hydrogen, R.sub.1 means 2-methyl group and n is 2; and R.sub.6 is different from propionyl group when R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are hydrogen and n means 2. The compounds of the general formula (I) are therapeutically useful for the treatment of diseases arising from a hypofunction of the dopaminergic system.
本发明涉及一种新颖的1,4-二取代哌嗪衍生物,其一般式为(I),其中包括药学上可接受的酸加盐和季铵盐,以及含有它们的制药组合物和制备它们的方法。在一般式(I)中,R.sub.1、R.sub.2、R.sub.3和R.sub.4相同或不同,代表氢或卤素或三卤甲基、较低烷基、较低烷氧基、硝基、羟基、芳基烷氧基或1-(2-丙烯基-4-哌嗪基)基;R.sub.5代表氢或C.sub.1-4烷基;R.sub.6代表C.sub.3-6烷基、烯基、炔基或##STR2##基,其中R.sub.7表示C.sub.2-5烷基、烯基或炔基;n为2或3,具体规定如下:当R.sub.2、R.sub.3、R.sub.4和R.sub.5代表氢,R.sub.1表示2-氯且n为2时,R.sub.6与异丙基、正丁基和异丁基不同;当R.sub.2、R.sub.3、R.sub.4和R.sub.5代表氢,R.sub.1表示2-氯且n为2时,R.sub.6与异丙基不同;或当R.sub.2、R.sub.3、R.sub.4和R.sub.5代表氢,R.sub.1表示2-甲基且n为2时,R.sub.6与异丙基不同;当R.sub.1、R.sub.2、R.sub.3、R.sub.4和R.sub.5均为氢,n为2时,R.sub.6与丙酰基不同。一般式(I)的化合物在治疗起因于多巴胺能系统低功能的疾病方面有治疗用途。